HSV-8 M

Herpes Simplex Virus-8 Mosaic Recombinant
Shipped with Ice Packs
In Stock

Description

Production and Quality Control

The antigen is produced in E. coli and purified via proprietary chromatographic methods. Key quality metrics include:

  • High Specificity: Immunoreactive with sera from HSV-8-infected individuals.

  • Stability: Maintains functionality under recommended storage conditions but degrades with repeated freezing .

Research and Diagnostic Applications

While HSV-8 M is primarily marketed as a diagnostic tool, its design reflects broader research interests in herpesvirus immunology:

Serological Testing

  • ELISA: Used to detect IgG/IgM antibodies against HSV-8 in patient sera.

  • Western Blotting: Validates antibody specificity by resolving antigen-protein interactions.

Limitations and Considerations

  • Nomenclature Confusion: The term "HSV-8" is non-standard; human herpesviruses are typically designated as HHV-8 (Human Herpesvirus 8). This may lead to misinterpretation in literature searches.

  • Cross-Reactivity: The antigen’s specificity for HSV-8 over other herpesviruses (e.g., HHV-8) requires validation in clinical settings.

Comparative Analysis with HHV-8

AspectHSV-8 M (Mosaic Antigen)HHV-8 (Kaposi’s Sarcoma-Associated Herpesvirus)
DesignRecombinant protein for antibody detectionHuman pathogen linked to Kaposi’s sarcoma, PEL, MCD
ApplicationsDiagnostic assaysOncology research, virology studies
Key ProteinsORF65, ORF8LANA (ORF73), vFLIP (ORF K13), vIL-6, vGPCR
TransmissionN/A (diagnostic use only)Saliva, sexual contact, organ transplantation

Future Directions

  • Limited Data: No peer-reviewed studies validate its efficacy beyond manufacturer claims.

  • Nomenclature Ambiguity: Confusion with HHV-8 necessitates clear distinction in experimental protocols.

For comprehensive studies, researchers should cross-reference results with HHV-8-specific assays (e.g., LANA-based immunohistochemistry ) to avoid misinterpretation.

Product Specs

Introduction
Herpes simplex virus (HSV) entry into host cells is mediated by interactions between viral glycoproteins and cell surface receptors. The virus particle's envelope, upon binding to specific cell surface receptors, fuses with the cell membrane. This fusion creates a pore, facilitating viral entry into the host cell. HSV entry unfolds in a sequential manner, mirroring other viruses. Initially, complementary receptors on the virus and cell surface draw the membranes close. Subsequently, the membranes begin to merge, leading to a hemifusion state. Finally, a stable entry pore forms, allowing the viral envelope contents to enter the host cell.
Description
This recombinant protein, derived from E. coli, encompasses the C-terminal immunodominant regions of ORF65 (amino acids 140-170) and the N-terminal regions of ORF8 (amino acids 32-62). It is fused with a GST tag.
Purity
The purity of the HSV-8 Mosaic protein exceeds 95%, as determined by 10% SDS-PAGE analysis with Coomassie blue staining.
Physical Appearance
Sterile filtered, clear solution.
Formulation
The protein is formulated in a buffer containing 100mM NaCl, 0.1% SDS, and 50% glycerol.
Stability
For optimal stability, HSV-8 Mosaic protein should be stored below -18°C. While it can remain stable at 4°C for up to one week, repeated freeze-thaw cycles should be avoided.
Applications
HSV-8 Mosaic antigen is well-suited for use in ELISA and Western blot applications. It serves as an excellent antigen for the detection of HSV, exhibiting minimal specificity issues.
Purification Method
HSV-8 Mosaic was purified by proprietary chromatographic technique.
Specificity
Immunoreactive with sera of HSV-8 infected individuals.

Q&A

What methodologies are most effective for detecting HHV-8 in clinical samples?

Polymerase Chain Reaction (PCR) remains the gold standard for HHV-8 detection in clinical samples. For optimal sensitivity, researchers should consider using quantitative PCR techniques such as Taqman® RT and Taqman® PCR with Amplitaq Gold® reagents . When designing primers, those that detect both spliced and non-spliced latent transcripts (such as lat-273F, lat-335R, and lat-294T) provide the highest sensitivity, consistently able to detect 1 infected cell in 10^5 uninfected cells . For oral samples specifically, daily home oral swab collection followed by PCR quantification has proven effective in longitudinal studies .

How does HHV-8 transmission occur within families and communities?

HHV-8 is primarily acquired through horizontal transmission during childhood, with intrafamilial contacts playing a crucial role. Research methodologies to study transmission should include:

  • Comprehensive serological testing of all household members

  • Age-stratified analysis to identify transmission patterns

  • Multivariate logistic regression models to control for potential confounders

Data reveals that children living with HHV-8-seropositive parents have significantly higher odds of being HHV-8 positive (OR=1.8, 95% CI: 1.3–2.5 with one seropositive parent; OR=2.5, 95% CI: 1.5–4.1 with two seropositive parents) . The impact is even stronger when multiple HHV-8-seropositive children under 14 years are in the household (OR=3.1, 95% CI: 1.8–5.3 for households with ≥2 seropositive children) .

What is the relationship between HHV-8 and other herpesviruses in population studies?

Cross-sectional studies of herpesvirus co-infection suggest potential interactions between HHV-8 and other herpesviruses. The most significant association appears to be with HSV-1, where HHV-8 seropositivity is significantly higher among HSV-1 positive individuals (30.4% vs. 14.5%; adjusted OR=2.1, 95% CI: 1.2-3.5) . Weaker associations exist with EBV (adjusted OR=2.1, 95% CI: 0.91-4.8) and CMV (adjusted OR=2.0, 95% CI: 0.96-4.2) . These findings suggest that common transmission routes or immunological interactions may exist between different herpesviruses, highlighting the importance of testing for multiple viral infections in epidemiological studies.

How should researchers approach the quantification and characterization of HHV-8 oral shedding dynamics?

Researchers studying HHV-8 oral shedding dynamics should implement a rigorous longitudinal sampling methodology. This approach should include:

  • Daily oral swab collection for at least 4 weeks

  • Quantitative PCR to determine viral copy number

  • Participant stratification by relevant clinical parameters (e.g., HIV status, KS status)

  • Calculation of shedding rates (days with HHV-8 detected divided by total days with samples)

  • Statistical analysis using hurdle models to account for zero-inflated data

Recent research demonstrates remarkable heterogeneity in shedding patterns, with some individuals showing low-viral load intermittent shedding and others exhibiting high-viral load persistent shedding . Importantly, shedding rates positively correlate with median viral loads, and episode duration correlates with peak viral load . When comparing different clinical groups, researchers should examine both the frequency of detection and the quantitative viral load measurements.

What animal models are available for HHV-8 research, and how should they be implemented?

The SCID-hu Thy/Liv mouse model represents an important system for studying HHV-8 infection in vivo. This model uses C.B-17 scid/scid mice implanted with human fetal thymus and liver grafts . Key methodological considerations include:

  • Direct inoculation of KSHV virions into the human tissue implants

  • Monitoring of viral DNA and mRNA production using real-time quantitative PCR

  • Controls including UV-irradiated inoculum to confirm active viral replication

  • Cell sorting to identify tropism in specific lymphocyte populations

  • Potential co-infection studies with HIV-1

This model successfully recapitulates the biphasic infection pattern observed in humans, with an early phase of lytic replication followed by sustained latency . The predominant viral gene expression occurs in CD19+ B lymphocytes, mirroring the natural tropism of the virus . While disease manifestations have not been observed in this model, it provides a valuable platform for studying viral replication and potential therapeutic interventions.

How does HIV status influence HHV-8 shedding and transmissibility?

HIV's impact on HHV-8 shedding presents a complex research challenge requiring careful methodological approaches. Current evidence suggests that while HIV status affects the likelihood of HHV-8 detection, it does not significantly alter shedding rates once infection is established.

In population studies, HIV seropositivity showed no significant association with HHV-8 seropositivity (adjusted OR=1.3, 95% CI: 0.79-2.0) . This suggests that while HIV may impact HHV-8 pathogenesis, its effect on transmission may be limited.

What are the correlates of HHV-8 seropositivity in adults, and how do they differ by demographic factors?

Research into HHV-8 seropositivity correlates requires careful demographic stratification and multivariate analysis. Key findings include:

  • Age-associated increases in seroprevalence, from 37% in those 14-19 years to 49% in those ≥50 years

  • Higher seroprevalence in men (43%) compared to women (38%)

  • Complex household density associations

Demographic FactorHHV-8 SeroprevalenceStatistical Significance
Age 14-19 years37% (118/321)P=.01 (trend across age groups)
Age ≥50 years49% (147/298)
Males43%P=.04 (compared to females)
Females38%

What statistical approaches are most appropriate for analyzing heterogeneous HHV-8 shedding patterns?

Given the heterogeneous nature of HHV-8 shedding, researchers should employ specific statistical approaches:

  • Hurdle models to account for zero-inflated data in shedding rate analyses

  • Correlation analyses between individual shedding rates and median viral loads

  • Stratification by relevant clinical parameters to identify group differences

  • Multivariate logistic regression to adjust for potential confounders in transmission studies

When analyzing shedding patterns, researchers should consider both the binary outcome (detection vs. non-detection) and the quantitative outcome (viral load when detected). This two-pronged approach can reveal important patterns that might be missed with simpler analytical methods.

How should researchers design studies to differentiate between various HHV-8 transmission routes?

To effectively differentiate between transmission routes, researchers should implement comprehensive study designs that:

  • Collect detailed household demographic and relationship data

  • Perform serological testing on all household members

  • Gather information on potential transmission behaviors (e.g., premastication of food)

  • Include age-stratified analyses to identify childhood vs. adult acquisition patterns

  • Examine correlations with other sexually and non-sexually transmitted infections

Research has demonstrated that HHV-8 transmission in children is strongly associated with the number of HHV-8-seropositive household members, particularly when both parents are seropositive (adjusted OR=3.4, 95% CI: 1.9-6.1) . Interestingly, studies examining specific potential transmission behaviors, such as maternal food premastication, have found no significant associations with HHV-8 seropositivity .

In adults, the lack of association between sexual behavior indicators and HHV-8 seropositivity suggests that horizontal non-sexual transmission may remain important even in adulthood . The differential association of HBcAb seropositivity with HHV-8 in women but not men suggests potential gender-specific transmission dynamics requiring further investigation.

How can improved understanding of HHV-8 shedding dynamics inform vaccine development strategies?

Understanding oral HHV-8 viral dynamics provides critical insights for vaccine development . Key research approaches should:

  • Characterize the heterogeneity in shedding patterns across different populations

  • Identify correlates of high viral load and persistent shedding

  • Determine how viral shedding relates to transmission risk

  • Investigate immune correlates of viral control

The finding that persistent shedding correlates with higher median viral loads regardless of HIV and KS status suggests that vaccines targeting the reduction of viral load may be effective in limiting transmission. Research should also explore whether the identified heterogeneity in shedding patterns relates to viral genetic diversity, host factors, or a combination of both.

What are the methodological challenges in studying HHV-8 gene expression in specific cell populations?

Investigating HHV-8 gene expression in specific cell populations presents several methodological challenges. Based on experimental models, researchers should consider:

  • Cell sorting techniques to isolate specific lymphocyte populations (e.g., CD19+ B cells)

  • Quantitative RNA detection methods that can distinguish between latent and lytic transcripts

  • Single-cell analysis approaches to account for heterogeneity within cell populations

  • Correlation of in vitro findings with in vivo observations

The SCID-hu Thy/Liv mouse model has demonstrated that viral gene expression is most abundant in CD19+ B lymphocytes, mimicking the natural tropism of the virus . Future studies should leverage single-cell technologies to further dissect the heterogeneity of HHV-8 infection within specific cell populations and across different tissues.

Product Science Overview

Introduction

Herpes Simplex Virus-8 (HSV-8), also known as Kaposi’s Sarcoma-associated Herpesvirus (KSHV), is a member of the Herpesviridae family. It is a double-stranded DNA virus that is primarily associated with Kaposi’s Sarcoma, a type of cancer that often affects individuals with compromised immune systems, such as those with HIV/AIDS. The virus is also linked to other malignancies, including primary effusion lymphoma and multicentric Castleman’s disease.

Structure and Composition

The HSV-8 Mosaic Recombinant is a recombinant protein derived from the Herpes Simplex Virus-8. It contains specific immunodominant regions from the viral proteins ORF65 and ORF8. The recombinant protein is typically produced in Escherichia coli (E. coli) and is fused with a Glutathione S-transferase (GST) tag to facilitate purification and detection .

Preparation Methods

The preparation of HSV-8 Mosaic Recombinant involves several steps:

  1. Gene Cloning: The genes encoding the immunodominant regions of ORF65 and ORF8 are cloned into an expression vector that includes a GST tag.
  2. Expression: The recombinant vector is introduced into E. coli cells, which are then cultured to express the recombinant protein.
  3. Purification: The expressed protein is purified using chromatographic techniques, leveraging the GST tag for affinity purification. The resulting protein is typically greater than 95% pure as determined by polyacrylamide gel electrophoresis (PAGE) with Coomassie staining .
Applications

The HSV-8 Mosaic Recombinant protein is widely used in research and diagnostic applications:

  • ELISA and Western Blots: It serves as an antigen for detecting antibodies against HSV-8 in serum samples, making it valuable for diagnostic assays.
  • Immunological Studies: The protein is used to study the immune response to HSV-8, helping to understand the virus’s pathogenesis and immune evasion strategies .
Stability and Storage

The HSV-8 Mosaic Recombinant protein is stable at 4°C for up to one week but should be stored below -18°C for long-term preservation. It is important to avoid repeated freeze-thaw cycles to maintain its integrity .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.